-The Times of India MUMBAI: It's widely known that a month's dose of cancer drugs can cost lakhs, but what isn't common knowledge is that Tata Memorial Hospital's doctors are working on alternatives that could cost less than Rs 1,000 a month. Dubbed the metronomic treatment protocol, it comprises daily consumption of a combination of low-dose medicines that are cheap because they have been around for decades. "There is no need to...
More »SEARCH RESULT
Total Matching Records found : 188
Indian pharma's generic challenge-DG Shah
-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...
More »Health gap between countries is narrowing, but challenges remain–UN report
-The United Nations The health gap between poor and rich countries has narrowed significantly over the past two decades according to a United Nations report released today, which stresses that in spite of this progress, challenges still remain to achieve the health targets of the Millennium Development Goals (MDGs). "Intensive efforts to achieve the MDGs have clearly improved health for people all over the world," said the Director-General of the World Health...
More »The Larger Implications of the Novartis Glivec Judgment-Sudip Chaudhuri
-Economic and Political Weekly The Supreme Court judgment on the Novartis-Glivec case is remarkable because it has gone beyond the specific technical and legal issues surrounding patents and has put the matter in a much larger political and economic perspective. The deeper implication of the judgment is that it is not only justified to deny patents when incremental innovation is trivial as in the Glivec case. The judgment has linked the...
More »The Cost of Drugs: Beyond the Supreme Court Order -Sanjay Nagral
-Economic and Political Weekly While the Supreme Court decision in the recent Novartis case has cleared the way for production of generic drugs in India, doctors have to prescribe cheaper alternatives to costly brands if patients with limited means are to benefit. What is being hailed as a victory in the struggle for Affordable Medicines in the country will actually be one only when there is a pro-patient slant to the...
More »
